pISSN 2234-3806eISSN 2234-3814
Table. 1.
Characteristics of 53 patients with metastatic PDAC
| Characteristic | Total (N=53) |
ctDNA non-responders (N=13) |
ctDNA responders (N=17) |
ctDNA negatives (N=23) |
P |
|---|---|---|---|---|---|
| Age, yrs, median (IQR) | 63 (60–68) | 68 (63–70) | 62 (55–72) | 63 (59.5–68) | 0.073 |
| Sex, N (%) | |||||
| Male | 32 (60.4) | 12 (22.6) | 9 (17.0) | 11 (20.8) | 0.022 |
| Female | 21 (39.6) | 1 (1.9) | 8 (15.1) | 12 (22.6) | |
| Number of metastatic sites, N (%) | |||||
| Single | 25 (47.2) | 4 (7.5) | 8 (15.1) | 13 (24.5) | 0.339 |
| Multiple | 28 (52.8) | 9 (17.0) | 9 (17.0) | 10 (18.9) | |
| First-line chemotherapy, N (%) | |||||
| FOLFIRINOX |
46 (86.8) | 10 (18.9) | 16 (30.2) | 20 (37.7) | 0.448 |
| Gemcitabine + nab-paclitaxel | 7 (13.2) | 3 (5.65) | 1 (1.9) | 3 (5.65) | |
| CA19-9, U/mL, median (IQR) | 402 (69.5–1,764) | 2,125 (126–5,990) | 292 (120–988) | 238 (44.25–598) | 0.122 |
*Of the 46 patients treated with FOLFIRINOX, nine received a modified regimen.
Abbreviation: IQR, interquartile range; FOLFIRINOX, combination of folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin; PDAC, pancreatic ductal adenocarcinoma.
Ann Lab Med 2025;45:199~208 https://doi.org/10.3343/alm.2024.0345
© Ann Lab Med